Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Prevalence of BRCA1 and BRCA2 Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer.

Tytuł:
Prevalence of BRCA1 and BRCA2 Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer.
Autorzy:
Vargas E; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
de Deugd R; CENTOGENE GmbH, Rostock, Germany.
Villegas VE; Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogota, Colombia.
Gil F; Unit of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogota, Colombia.
Mora L; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
Viaña LF; Cancer League, Cartagena, Colombia.
Bruges R; Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia.
Gonzalez A; Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia.
Galvis JC; Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia.
Hamann U; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Torres D; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Źródło:
The oncologist [Oncologist] 2022 Mar 04; Vol. 27 (2), pp. e151-e157.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2022- : Oxford : Oxford University Press
Original Publication: Dayton, Ohio : AlphaMed Press, c1996-
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/epidemiology
Breast Neoplasms*/genetics
Germ-Line Mutation*
Colombia/epidemiology ; Female ; Humans ; Prevalence
References:
Nat Rev Dis Primers. 2019 Sep 23;5(1):66. (PMID: 31548545)
Nat Rev Cancer. 2007 Dec;7(12):937-48. (PMID: 18034184)
Fam Cancer. 2018 Jan;17(1):23-30. (PMID: 28528518)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Hum Genet. 2003 Oct;113(5):452-60. (PMID: 12942367)
Breast Cancer Res Treat. 2007 Jun;103(2):225-32. (PMID: 17080309)
Breast Cancer Res Treat. 2008 Nov;112(2):353-8. (PMID: 18176857)
Biotechniques. 1994 Aug;17(2):316, 318, 320-2. (PMID: 7980935)
Breast Cancer Res Treat. 2015 Dec;154(3):441-53. (PMID: 26564481)
Gynecol Oncol. 2012 Feb;124(2):236-43. (PMID: 22044689)
PLoS Genet. 2014 Sep 25;10(9):e1004572. (PMID: 25254375)
Am J Hum Genet. 1998 Jun;62(6):1381-8. (PMID: 9585613)
Hered Cancer Clin Pract. 2014 Apr 17;12(1):11. (PMID: 24742220)
PLoS Genet. 2013 Nov;9(11):e1003925. (PMID: 24244192)
Breast Cancer Res Treat. 2009 May;115(2):315-23. (PMID: 18546071)
Biol Res. 2017 Oct 6;50(1):35. (PMID: 28985766)
Oncologist. 2019 Jul;24(7):e475-e479. (PMID: 30541753)
Colomb Med (Cali). 2018 Mar 30;49(1):16-22. (PMID: 29983460)
Cancer. 2009 May 15;115(10):2222-33. (PMID: 19241424)
Sci Rep. 2017 Jul 5;7(1):4713. (PMID: 28680148)
PLoS Genet. 2008 Mar 21;4(3):e1000037. (PMID: 18369456)
Breast Cancer Res Treat. 2015 Jan;149(1):31-9. (PMID: 25428789)
Hum Genet. 2000 Aug;107(2):186-91. (PMID: 11030417)
Sci Rep. 2018 Jun 15;8(1):9188. (PMID: 29907814)
Breast Cancer Res. 2020 Oct 21;22(1):108. (PMID: 33087180)
Contributed Indexing:
Keywords: BRCA1/2; Afro-Colombian; breast cancer; germline mutation
Substance Nomenclature:
0 (BRCA1 Protein)
0 (BRCA1 protein, human)
0 (BRCA2 Protein)
0 (BRCA2 protein, human)
SCR Disease Name:
Breast Cancer, Familial
Entry Date(s):
Date Created: 20220531 Date Completed: 20220602 Latest Revision: 20220716
Update Code:
20240105
PubMed Central ID:
PMC8895486
DOI:
10.1093/oncolo/oyab026
PMID:
35641219
Czasopismo naukowe
Background: Pathogenic germline mutations in the BRCA1 and BRCA2 (BRCA1/2) genes contribute to hereditary breast/ovarian cancer (OC) in White/mestizo Colombian women. As there is virtually no genetic data on breast cancer (BC) in Colombians of African descent, we conducted a comprehensive BRCA1/2 mutational analysis of 60 Afro-Colombian families affected by breast/OC.
Materials and Methods: Mutation screening of the complete BRCA1/2 genes for small-scale mutations and large genomic alterations was performed in these families using next-generation sequencing and multiplex ligation-dependent probe amplification analysis.
Results: Four pathogenic germline mutations, including one novel mutation, were identified, comprising 3 in BRCA1 and one in BRCA2. The prevalence of BRCA1/2 mutations, including one BRCA1 founder mutation (c.5123C>A) previously identified in this sample set, was 3.9% (2/51) in female BC-affected families and 33.3% (3/9) in those affected by both breast and OC. Haplotype analysis of 2 BRCA2_c.2701delC carriers (one Afro-Colombian and one previously identified White/mestizo Colombian patient with BC) suggested that the mutation arose in a common ancestor.
Conclusion: Our data showed that 2/5 (40%) mutations (including the one previously identified in this sample set) are shared by White/mestizo Colombian and Afro-Colombian populations. This suggests that these 2 populations are closely related. Nevertheless, variations in the BRCA1/2 mutational spectrum among Afro-Colombian subgroups from different regions of the country were observed, suggesting that specific genetic risk assessment strategies need to be developed.
(© The Author(s) 2022. Published by Oxford University Press.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies